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Abstract
Background: There is a paucity of recent epidemiological data on bone cancers. The aim of this study was to describe 
incidence and survival patterns for bone cancers diagnosed during 1981 - 2002.
Methods: Cases aged 0 - 39 years (236 osteosarcomas, 166 Ewing sarcomas and 73 chondrosarcomas) were analysed 
using Poisson and Cox regressions.
Results: Incidence rates (per million persons per year) for osteosarcoma were 2.5 at age 0 - 14 years; 4.5 at age 15 - 29 
years and 1.0 at age 30 - 39 years. Similarly, for Ewing sarcoma the incidence rates were 2.2; 2.9; 0.4 and for 
chondrosarcoma rates were 0.1; 1.2; 1.8 respectively. Incidence of osteosarcoma increased at an average annual rate of 
2.5% (95% CI 0.4 - 4.7; P = 0.02), but there was no change in incidence of Ewing sarcoma or chondrosarcoma. There was 
a marginally statistically significant improvement in survival for Ewing sarcoma (hazard ratio (HR) per annum = 0.97; 
95% CI 0.94 - 1.00; P = 0.06), although patients aged 15 - 39 years (n = 93) had worse overall survival than those aged 0 - 14 (n 
= 73; HR = 1.46; 95% CI 0.98 - 2.17; P = 0.06). There was no significant improvement in osteosarcoma survival (HR per 
annum = 0.98; 95% CI 0.95 - 1.01; P = 0.18).
Conclusions: Reasons for poorer survival in Ewing sarcoma patients aged 15 - 39 years and failure to significantly 
improve survival for osteosarcoma patients requires further investigation.
Background
Malignant bone tumours comprise 0.7% of all cancer
diagnoses in the UK [1]. For all ages they have an age-
standardised rate of 8 per 1,000,000 persons per year in
males and 6 per 1,000,000 persons per year in females
(standardised to the world population [2]). These
tumours are the third most frequently occurring malig-
nancy diagnosed in those aged 10 - 24 years and comprise
more than twenty diagnostic sub-groups. Osteosarcoma
is the most common sub-group, accounting for around a
third of all diagnoses [3,4].
Primary bone cancer is rarely diagnosed in children
before the age of five or adults over the age of sixty [3].
Incidence of osteosarcoma increases with age until a peak
in late childhood or adolescence around the time of
puberty, after which incidence declines. A second less
pronounced peak occurs in older adults aged more than
65 years. Ewing sarcoma has an incidence peak in the late
teenage years, whilst chondrosarcoma peaks in older
adults (aged > 65 years) [4-6]. A small number of studies
have explored the incidence and survival of childhood
bone cancer [7-15]. However, even fewer studies have
examined incidence and survival in those aged over 24
years.
We have previously analysed incidence and survival of
bone cancer in children (aged 0 - 14 years) from northern
England and the West Midlands [15]. The aim of the
present study was to extend the age range analysed to
include cases aged up to 39 years old. It is important to
analyse this age-range as the incidence of both osteosar-
coma and Ewing sarcoma peak after childhood (in those
aged more than 15 years). We describe the incidence and
survival from osteosarcoma, chondrosarcoma and Ewing
sarcoma diagnosed in 0 - 39 year olds in northern Eng-
land during the period 1981 - 2002 and compare patients
aged 15 - 39 years with those aged 0 - 14 years. It should
be noted that the childhood cases aged 0 - 14 years from
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the region were also included in the previous analysis (82
osteosarcoma; 73 Ewing sarcoma; 2 chondrosarcoma)
[15]. The present study also updates previous analyses
from northern England and the whole of Great Britain
[9,16].
Methods
Study Subjects
Data were included for all patients aged 0 - 39 years regis-
tered during the period 1981 - 2002 by the Northern and
Yorkshire Cancer Registry and Information Service
(NYCRIS). This is a regional registry that records all cases
of cancer and covers an area in the north of England with
a population of approximately 6.6 million. The registry is
population-based and has a very high level of ascertain-
ment due to rigorous data collection procedures [17].
NYCRIS receives notifications of all malignancies diag-
nosed in the region from a variety of sources, the main
source being pathology reports that are routinely submit-
ted by all health care providers (National Health Service
Trusts) in the area. Six months after diagnosis registry
staff visit the hospital of primary treatment to manually
extract additional clinical information from the patients'
case notes. They check that tumour deaths correspond
with the information on the original data source and
amend when necessary.
In our study, records of primary malignant bone
tumours registered between 1981 and 2002 in patients
aged 0 - 39 years were extracted from NYCRIS. All
tumours were categorised according to The World Health
Organization Classification of Tumours system [18]. Sec-
o n d a ry  a n d  be n i g n  bo n e  t u m o u r s  w e r e  e x c l u d e d  f r o m
this study. Information available for each case included
demographic data (sex; date of birth); tumour diagnosis
(date; site and morphology) and follow-up (current sta-
t u s ;  d a t e  o f  d e a t h ;  d a t e  o f  l a s t  f o l l o w - u p ) .  A n a l y s e s
focussed on the three main diagnostic sub-groups: osteo-
sarcoma; Ewing sarcoma and chondrosarcoma.
Statistical Methods
Age-specific incidence rates per million persons per year
were calculated based on annual mid-year population
estimates for the study region obtained from Office for
National Statistics. Comparisons of age-standardised
incidence rates (ASRs) are only meaningful if they are
standardised in the same way. The world standard has the
most widespread use and calculation of world ASRs
allows comparisons to be made with other published UK
and international (especially European) studies
[3,9,11,15]. ASRs were calculated using the age-specific
incidence rates for five-year age groups weighted using
the standard world population (originally proposed by
Segi, but modified by Doll and colleagues and con-
structed from the pooled populations of forty six repre-
sentative countries that had accurate population census
data) [2,19-21]. Poisson regression was used to model the
effects on incidence rate for time period of diagnosis
(1981 - 1988, 1989 - 1995, 1996 - 2002); age group (0 - 14,
15 - 29, 30 - 39 years) and sex. Cases were followed up
until 31st December 2005. Five-year survival rates were
calculated for all cases diagnosed during the period 1981
- 2000 as follow up was only available for all cases until
the end of 2005. Survival rates were calculated using
Kaplan-Meier estimation [22] and differences in survival
between diagnostic groups (osteosarcoma, Ewing sar-
coma and chondrosarcoma) assessed using log-rank tests.
Cox Proportional Hazards regression analysis was used to
model the probability of survival in relation to age, sex
and year of diagnosis. Statistical significance was taken to
be P < 0.05 and marginal significance as 0.05 ≤ P < 0.1 in
all analyses. All statistical analyses were performed using
Stata version 10.
Results
There were 509 patients aged less than 40 years diag-
nosed with a malignant bone tumour in the NYCRIS area
during the period 1981 to 2002. The number of cases and
age-standardised incidence rates by diagnostic group, sex
and age group are shown in Table 1. The most common
bone cancer sub-groups diagnosed in 0 - 39 year olds
were osteosarcoma (236 cases, by sub-type: 209 osteo-
blastic; 14 chondroblastic; 6 fibroblastic; 5 telangiectatic
and 2 small cell) and Ewing sarcoma (166 cases). These
comprised 46% and 33% of diagnoses respectively. Other
sub-groups were diagnosed in smaller numbers with 73
chondrosarcoma cases (14% of diagnoses; by sub-type: 71
central and 2 others) and 34 cases of other specified and
unspecified bone tumours (7%). The latter heterogeneous
group of other specified and unspecified tumours was not
analysed. Age standardised incidence rates per million
population years for each of the bone cancer sub-groups
were 2.97 (95% CI 2.59 - 3.35) for osteosarcoma; 0.78
(95% CI 0.60 - 0.96) for chondrosarcoma and 2.14 (95%
CI 1.82 - 2.47) for Ewing sarcoma.
Incidence varied by age group (Table 1). Poisson regres-
sion models showed that after adjustment for sex and
time period the incidence peaked among 15 - 29 year
olds. The incidence rate ratios (IRRs) for those aged 15 -
29 years relative to 0 - 14 years were 2.04 (95% CI 1.55 -
2.68) for osteosarcoma; 22.33 (95% CI 5.38 - 92.73) for
chondrosarcoma and 1.44 (95% CI 1.05 - 1.97) for Ewing
sarcoma. The IRRs relative to the 0 - 14 age group for
ages 30 - 39 were 0.45 (95% CI 0.28 - 0.75) for osteosar-
coma; 34.34 (95% CI 8.26 - 142.76) for chondrosarcoma
and 0.21 (95% CI 0.10 - 0.44) for Ewing sarcoma.
There were more male than female cases of all bone
cancer combined (310 males, 199 females; P < 0.001) and
for each of the sub-groups. The IRRs for males relative toEyre et al. BMC Cancer 2010, 10:357
http://www.biomedcentral.com/1471-2407/10/357
Page 3 of 7
females were 1.49 (95% CI 1.15 - 1.94) for osteosarcoma;
1.81 (95% CI 1.12 - 2.92) for chondrosarcoma and 1.42
(95% CI 1.04 - 1.93) for Ewing sarcoma.
The results of the analyses of time trends in bone can-
cer incidence during 1981 - 2002 are shown in Table 2.
There was a statistically significant increase in the inci-
dence of osteosarcoma of 2.54% per annum (95% CI 0.43
- 4.65; P = 0.02). There was little evidence for any tempo-
ral changes in the incidence rates for other diagnostic
groups.
Five-year survival rates by period of diagnosis by bone
cancer sub-group are shown in Table 3. For all bone can-
cers combined 57% (95% CI 52 - 61) of 0 - 39 year olds
survived for at least five years. Five-year survival rates for
diagnostic sub-groups were 58% (95% CI 51 - 64) for oste-
osarcoma; 71% (95% CI: 59 - 81) for chondrosarcoma and
43% (95% CI 35 - 51) for Ewing sarcoma. There was evi-
dence of significant differences in survival rates among
the diagnostic groups (log-rank test: P < 0.001). Signifi-
cantly better survival rates were found for chondrosar-
coma compared with osteosarcoma (P = 0.001) and for
osteosarcoma compared with Ewing sarcoma (P = 0.001)
(Figure 1).
Ewing sarcoma exhibited a higher risk of death for sub-
jects aged 15 - 39 than those aged 0 - 14 (HR = 1.46 95%
CI 0.98 - 2.17; P = 0.06) (Figure 2). After adjusting for age
in the Cox model, the overall risk of death was estimated
to decrease by 2.8% for each increasing year of diagnosis
(HR per annum = 0.97 95% CI 0.94 - 1.00; P = 0.06). There
was no evidence for differences in survival from Ewing
sarcoma between males and females (P = 0.83).
For osteosarcoma there was a non-statistically signifi-
cant improvement in survival during the study period
(HR per annum = 0.98; 95% CI 0.95 - 1.01; P = 0.18).
Table 1: Number of cases and age-standardised incidence rates (ASR) per million persons per year by diagnostic group, 
sex and age-group (in years), 1981-2002
0 - 14 15 - 29 30 - 39 0 - 39
N ASR (95% CI) N ASR (95% CI) N ASR (95% CI) ASR (95% CI)
Osteosarcoma All persons 82 2.48 (1.94,3.02) 135 4.53 (3.76,5.29) 19 0.98 (0.59,1.53) 2.97 (2.59,3.35)
Male 45 2.66 (1.88,3.44) 83 5.56 (4.36,6.76) 14 1.44 (0.79,2.41) 3.51 (2.93,4.09)
Female 37 2.30 (1.55,3.04) 52 3.49 (2.54,4.44) 5 0.52 (0.17,1.20) 2.42 (1.93,2.91)
Chondrosarcoma All persons 2 0.06 (0.01,0.23) 36 1.17 (0.79,1.55) 35 1.80 (1.20,2.40) 0.78 (0.60,0.96)
Male 1 0.06 (0.00,0.32) 23 1.50 (0.95,2.25) 23 2.38 (1.51,3.57) 1.00 (0.71,1.29)
Female 1 0.07 (0.00,0.38) 13 0.83 (0.44,1.42) 12 1.22 (0.63,2.14) 0.55 (0.36,0.81)
Ewing sarcoma All persons 73 2.24 (1.73,2.76) 85 2.85 (2.24,3.46) 8 0.41 (0.18,0.82) 2.14 (1.82,2.47)
Male 40 2.42 (1.67,3.17) 54 3.62 (2.66,4.59) 4 0.42 (0.11,1.07) 2.51 (2.01,3.01)
Female 33 2.06 (1.35,2.76) 31 2.08 (1.34,2.81) 4 0.41 (0.11,1.05) 1.77 (1.35,2.20)
Table 2: Number of cases and age-standardised incidence rates (ASR) per million persons per year by diagnostic group, 
sex and time period
1981 - 1988 1989 - 1995 1996 - 2002 %annual
N ASR (95% CI) N ASR (95% CI) N ASR (95% CI) change Pa
Osteosarcoma All persons 82 2.65 (2.07,3.22) 71 2.85 (2.18,3.52) 83 3.51 (2.75,4.28) 2.54% 0.02
Male 48 3.03 (2.17,3.88) 44 3.44 (2.41,4.46) 50 4.28 (3.08,5.47) 3.13% 0.08
Female 34 2.27 (1.50,3.03) 27 2.26 (1.48,3.30) 33 2.74 (1.79,3.69) 1.75% 0.30
Chondrosarcoma All persons 37 1.10 (0.75,1.46) 14 0.46 (0.25,0.78) 22 0.74 (0.46,1.13) -0.80% 0.71
Male 20 1.19 (0.72,1.83) 9 0.58 (0.26,1.11) 18 1.23 (0.72,1.97) 2.75% 0.51
Female 17 1.02 (0.59,1.63) 5 0.35 (0.10,0.82) 4 0.26 (0.07,0.66) -3.77% 0.14
Ewing sarcoma All persons 73 2.44 (1.88,3.00) 42 1.75 (1.22,2.29) 51 2.21 (1.60,2.83) -0.44% 0.72
Male 42 2.77 (1.93,3.61) 29 2.40 (1.60,3.46) 27 2.37 (1.55,3.45) -1.00% 0.47
Female 31 2.11 (1.36,2.86) 13 1.09 (0.58,1.87) 24 2.06 (1.31,3.08) 0.51% 0.82
a. P value for test of no annual changeEyre et al. BMC Cancer 2010, 10:357
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Table 3: Percentage five-year survival for 0-39 year olds by diagnostic group, sex and time perioda
1981 - 1987 1988 - 1994 1995 - 2000
Rate (95% CI) Rate (95% CI) Rate (95% CI)
Osteosarcoma All persons 49 (38,61) 61 (49,72) 62 (50,73)
Male 47 (32,62) 54 (38,68) 53 (37,67)
Female 54 (35,72) 71 (52,84) 76 (56,88)
Chondrosarcoma All persons 71 (51,85) 67 (43,83) 76 (49,90)
Male 75 (42,91) 63 (36,82) 77 (45,92)
Female 69 (42,86) 80 (25,96) 75 (18,96)
Ewing sarcoma All persons 37 (26,50) 46 (32,60) 49 (33,65)
Male 35 (22,52) 47 (30,65) 50 (29,71)
Female 40 (23,60) 44 (22,69) 47 (25,70)
a. Rates data include 95% CI in parentheses
Figure 1 Kaplan-Meier Survival by diagnosis group.
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There was no significant evidence that sex (P = 0.11) or
age (P = 0.50) had any effect on survival. Survival rates for
chondrosarcoma remained constant (HR per annum =
1.00; 95% CI 0.94 - 1.07; P = 0.89) and there was no evi-
dence that sex (P = 0.46) or age (P = 1.00) had any signifi-
cant effect on survival.
Discussion
This study of primary bone cancer in 0 - 39 years olds in
northern England is the most recent analysis that has
examined incidence and survival for this age group. Cases
were limited to those aged less than forty years because
this is the upper age-limit for entry into most clinical tri-
als [16,23]. Furthermore, this age range coincides with the
peak age-incidence distribution for the majority of malig-
nant primary bone tumours. It is likely that a substantial
proportion of the 0 - 39 year old patients have been
treated according to trial protocols (although we did not
have access to data on trial entry). The basic case inci-
dence and survival data were accurately recorded by the
registry. However, data on stage and treatment were not
consistently and reliably recorded. Therefore, some of the
differences in survival may be due to differences in case
mix with respect to stage or treatment regime.
Although there is some evidence for an improvement in
survival from Ewing sarcoma during the period 1981 -
2000, cases aged 15 - 39 years had worse outcome than
those aged 0 - 14 years. In contrast, for osteosarcoma,
there was no significant change in survival throughout
the study period and no evidence that cases aged 15 - 39
years had worse outcome than childhood cases (aged 0 -
14 years).
The incidence rates reported in the present study were
similar to those reported in other countries with mainly
white populations. In addition, the predominance of oste-
osarcoma and Ewing sarcoma found in this study are also
typical patterns reported in ethnically similar populations
(5% were minority ethnic population) [24,25].
Incidence of osteosarcoma, chondrosarcoma and
Ewing sarcoma was higher among males than females.
This is consistent with previous literature, which has
reported that although males and females tend to show
Figure 2 Kaplan-Meier Survival for Ewing Sarcoma by age-group (in years).
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similar incidences in childhood [11,15,24], when an
extended age range is included, all three diagnostic
groups are more common in males [25].
Osteosarcoma and Ewing sarcoma both had incidence
peaks in the 15 - 29 age group. This is consistent with
previous studies, which have widely reported incidence of
these two diagnostic groups to rise after the onset of
puberty, when young people are undergoing a growth
spurt and bones experience rapid growth [8,11,24].
This study found an increase in the incidence of osteo-
sarcoma, but no temporal changes in the incidence of
Ewing sarcoma and chondrosarcoma during the period
1981 - 2002. In both the USA and Europe, overall bone
cancer incidence across all age groups has been reported
to have remained steady over the last 30 years [25,26].
We have previously analysed the survival of children
resident in northern England and the West Midlands dur-
ing the same time period [15]. For children we found that
whilst there was an improvement in survival from Ewing
sarcoma, there was no improvement for osteosarcoma.
The present study confirms that the lack of improvement
in survival for osteosarcoma also applies at ages 15 - 39
years. However, it has indicated a worse outcome for
Ewing sarcoma cases in age group 15 - 39 years. Another
recent study from the USA analysed data from the Sur-
veillance, Epidemiology and End Results Program and
has found that there has been no statistically significant
improvement in survival from osteosarcoma (at all ages)
from 1984 to 2004 [27].
The most recent national data from Great Britain
reported five-year survival rates of 53% and 51% for cases
aged 0 - 39 years during 1990 - 1994 [16]. Our data have
shown that survival for northern England was better for
osteosarcoma (58%) but worse for Ewing sarcoma (43%).
Data for patients of all ages, from the United States
National Cancer Database, also reported worse five-year
survival (51.2%) for osteosarcoma and better five-year
survival (50.2%) for Ewing sarcoma [28]. Better survival of
osteosarcoma compared with the US study is likely to be
due to the exclusion of patients aged more than 40 years
from the present study. Another study of osteosarcoma
from Finland reported five-year survival of 65% during
1981 - 1990 [29]. However, survival rates in northern
England were similar to 15 - 24 year olds from a multi-
centre (twenty countries) European study, which found
five-year survival rates of 58% for osteosarcoma and 42%
for Ewing sarcoma [30].
A number of studies have reported worse survival from
osteosarcoma in adults aged more than forty years
[27,28,31,32]. It is very well recognized that those aged
more than 40 years have poorer prognosis than younger
patients [33]. In our study of 0 - 39 year olds, we only
found worse outcome for cases of Ewing sarcoma aged 15
- 39 years, but not for osteosarcoma. However, some
other studies have specifically studied adolescent and
young adult cases and have indicated worse outcome in
this age group for both osteosarcoma and Ewing sarcoma
compared with children [22,34,35].
The worse survival in cases of Ewing sarcoma aged 15 -
39 years is consistent with previous studies and may be
due to a number of different factors including treatment,
delays in diagnosis, metastatic disease, site and the stage
of the tumour [36-39]. We were not able to investigate
these factors within the scope of the present study. How-
ever, these issues will be addressed in future studies that
focus on the Teenage and Young Adult (TYA) age group.
A special National Cancer Research Institute TYA Clini-
cal Studies Development Group has been formed and will
oversee analyses of a new national TYA cancer dataset.
Conclusion
This study has found an increase in the incidence of oste-
osarcoma, but no change in the incidence of Ewing sar-
coma or chondrosarcoma. There was a lack of improved
survival from osteosarcoma in both childhood and young
adult cases and worse survival in Ewing sarcoma patients
aged 15 - 39 years compared to those aged 0 - 14 years.
Further research is needed to elicit the reasons for the
failure to improve survival for osteosarcoma patients and
for worse survival in older Ewing sarcoma patients.
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